Related Experiment Video
Updated: Jul 22, 2025
06:03
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
1.3K
Comment on "Reactogenicity Study of mRNA COVID-19 Vaccine"
Amnuay Kleebayoon1, Viroj Wiwanitkit2
1private academic consultant, KH. amnuaykleebai@gmail.com.
Archivos De Prevencion De Riesgos Laborales
|July 24, 2023
Summary
This study compared mRNA COVID-19 vaccines, finding Spikevax® (Moderna) had greater reactogenicity than Commirnaty® (Pfizer). Understanding these reactogenicity differences aids in planning effective COVID-19 vaccination strategies.
Area of Science:
- Immunology
- Vaccinology
Background:
- Compares reactogenicity of mRNA COVID-19 vaccines: Commirnaty® (Pfizer) and Spikevax® (Moderna).
- Focuses on a healthcare population to assess vaccine side effects.
Discussion:
- Spikevax® demonstrated higher reactogenicity than Commirnaty® for both doses.
- Second vaccine doses showed increased reactogenicity compared to first doses for both vaccines.
- Highlights the need for laboratory confirmation to differentiate between asymptomatic COVID-19 and lack of symptoms.
Key Insights:
- Greater reactogenicity observed with Spikevax® compared to Commirnaty®.
- Second vaccine doses are associated with heightened reactogenicity.
- Undiagnosed asymptomatic COVID-19 can complicate symptom interpretation.
Outlook:
- Further clinical studies are required to validate findings.
- Genetic variations may influence individual immune responses to COVID-19 vaccines.
- Results offer insights for optimizing COVID-19 vaccination campaign planning in healthcare settings.
